Faculté de Chimie, ULP, Strasbourg, FRANCE

Slides:



Advertisements
Similar presentations
L. Brillet (CEA) – ANR meeting – META08 Hammamet 1/18 validation ANR meeting - 28/10/2008 CEA Grenoble - DSV/iRTSV/CMBA.
Advertisements

Design of high-content and focused libraries to improve the development of new active compounds in the framework of the rational drug discovery Design.
1 Real World Chemistry Virtual discovery for the real world Joe Mernagh 19 May 2005.
Analysis of High-Throughput Screening Data C371 Fall 2004.
1 Sequential Screening S. Stanley Young NISS HTS Workshop October 25, 2002.
3D Molecular Structures C371 Fall Morgan Algorithm (Leach & Gillet, p. 8)
Faculté de Chimie, ULP, Strasbourg, FRANCE
A Multiobjective Approach to Combinatorial Library Design Val Gillet University of Sheffield, UK.
In silico small molecule discovery Sales Target gene Discover hit Hit to lead Optimise lead Clinical Target gene identified with a viable assay High throughput.
Department Author Lead-like Properties, High- throughput Screening and Combinatorial Library Design Andy Davis, Simon Teague, Tudor Oprea, John Steele,
Jürgen Sühnel Institute of Molecular Biotechnology, Jena Centre for Bioinformatics Jena / Germany Supplementary Material:
ABCD Flexsim-R: A new 3D descriptor for combinatorial library design and in-silico screening 2 nd Joint Sheffield Conference on Chemoinformatics: Computational.
What is similar?. Similarity and Diversity Alexandre Varnek, University of Strasbourg, France.
Lipinski’s rule of five
…ask more of your data 1 Bayesian Learning Build a model which estimates the likelihood that a given data sample is from a "good" subset of a larger set.
Establishing a Successful Virtual Screening Process Stephen Pickett Roche Discovery Welwyn.
Faculty of Computer Science © 2006 CMPUT 605February 04, 2008 Novel Approaches for Small Bio-molecule Classification and Structural Similarity Search Karakoc.
Cheminformatics II Apr 2010 Postgrad course on Comp Chem Noel M. O’Boyle.
Luddite: An Information Theoretic Library Design Tool Jennifer L. Miller, Erin K. Bradley, and Steven L. Teig July 18, 2002.
In-silico screening without structural comparisons: Peptides to non-peptides in one step Maybridge Workshop Oct ‘03 Bregenz Austria.
Design of Small Molecule Drugs Targeted to RNA RNA Ontology Group May
Super fast identification and optimization of high quality drug candidates.
2DS01 Statistics 2 for Chemical Engineering lecture 5.
In Silico Design of Selective Estrogen Receptor Modulators from Triazoles and Imines Joey Salisbury Dr. John C. Williams Small Molecules/Large Molecules.
Chemoinformatics in Drug Design
Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Drug Development
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
Structure-based Drug Design
Predicting Highly Connected Proteins in PIN using QSAR Art Cherkasov Apr 14, 2011 UBC / VGH THE UNIVERSITY OF BRITISH COLUMBIA.
Chemoinformatics approaches to virtual screening and in silico design Alexandre Varnek Laboratoire d’Infochimie, Université de Strasbourg
GGAGATTCTGGGCCACTTTGGTTCCCCATGAGCCAAGACGGCACTTCTAATTTGCATTCCCTACCGGAGTCCCTGTCTGTAGCCAGCCTGGCTTTCAGCTGGTGCCCAAAGTGACAAATGTATCTGCAATGACAAAGGTAC CCTGGAAGGGCTCGCCCTCTGCGGAATTTCAGTTCATGCAGGCCTTGGTGCTTCCACATCTGTCCAAGGGCCTTTCAAATGTGACTTTTAACTCTGTGGATTGATTTGCCCGG
Drug Design Process Discovery Phase. Tripos Software n SYBYL & its modules SYBYL, Concord, MOLCAD, SiteId, Advanced Computation, GASP, DISCOtech, HQSAR,
Computational Techniques in Support of Drug Discovery October 2, 2002 Jeffrey Wolbach, Ph. D.
Cédric Notredame (30/08/2015) Chemoinformatics And Bioinformatics Cédric Notredame Molecular Biology Bioinformatics Chemoinformatics Chemistry.
Combinatorial Chemistry and Library Design
Asia’s Largest Global Software & Services Company Genomes to Drugs: A Bioinformatics Perspective Sharmila Mande Bioinformatics Division Advanced Technology.
Topological Summaries: Using Graphs for Chemical Searching and Mining Graphs are a flexible & unifying model Scalable similarity searches through novel.
Introduction to Chemoinformatics Irene Kouskoumvekaki Associate Professor December 12th, 2012 Biological Sequence Analysis course.
EXPLORING CHEMICAL SPACE FOR DRUG DISCOVERY Daniel Svozil Laboratory of Informatics and Chemistry.
Genomics Research Institute University of Cincinnati Compound Library Wm. L. Seibel January 10, 2007.
Genome Research Institute University of Cincinnati.
High Throughput Experimentation: Computational Requirements John M. Newsam Molecular Simulations Inc. (A Pharmacopeia subsidiary) “Workshop on Combinatorial.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Virtual Screening at the post-genomic era Dr. Didier ROGNAN Bioinformatic Group UMR CNRS 7081 Illkirch, France.
Développement "IN SILICO" de nouveaux extractants et complexants de métaux Alexandre Varnek Laboratoire d’Infochimie, Université Louis Pasteur, Strasbourg,
Use of Machine Learning in Chemoinformatics Irene Kouskoumvekaki Associate Professor December 12th, 2012 Biological Sequence Analysis course.
Développement "IN SILICO" de nouveaux extractants et complexants de métaux Alexandre Varnek Laboratoire d’Infochimie, Université Louis Pasteur, Strasbourg,
In silico discovery of inhibitors using structure-based approaches Jasmita Gill Structural and Computational Biology Group, ICGEB, New Delhi Nov 2005.
Page 1 SCAI Dr. Marc Zimmermann Department of Bioinformatics Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) Grid-enabled drug discovery.
Ligand-based drug discovery No a priori knowledge of the receptor What information can we get from a few active compounds.
Combinatorial Chemistry. Synthesis of many structures (diversity) combinatorial technology, combinatorial library molecular diversity What is Combinatorial.
Virtual Screening C371 Fall INTRODUCTION Virtual screening – Computational or in silico analog of biological screening –Score, rank, and/or filter.
Bioinformatics MEDC601 Lecture by Brad Windle Ph# Office: Massey Cancer Center, Goodwin Labs Room 319 Web site for lecture:
Selecting Diverse Sets of Compounds C371 Fall 2004.
Computer-aided drug discovery (CADD)/design methods have played a major role in the development of therapeutically important small molecules for several.
Introduction to Chemoinformatics and Drug Discovery Irene Kouskoumvekaki Associate Professor February 15 th, 2013.
Développement "IN SILICO" de nouveaux extractants et complexants de métaux Alexandre Varnek Laboratoire d’Infochimie, Université Louis Pasteur, Strasbourg,
Use of Machine Learning in Chemoinformatics
Identification of structurally diverse Growth Hormone Secretagogue (GHS) agonists by virtual screening and structure-activity relationship analysis of.
Computational Approach for Combinatorial Library Design Journal club-1 Sushil Kumar Singh IBAB, Bangalore.
Shows tendency for mergers. These big companies may be shrinking – much research is now outsourced to low cost countries like Latvia, India, China and.
Elon Yariv Graduate student in Prof. Nir Ben-Tal’s lab Department of Biochemistry and Molecular Biology, Tel Aviv University.
Docking and Virtual Screening Using the BMI cluster
Molecular Modeling in Drug Discovery: an Overview
TIDEA Target (and Lead) Independent Drug Enhancement Algorithm.
Natural products from plants
Page 1 Computer-aided Drug Design —Profacgen. Page 2 The most fundamental goal in the drug design process is to determine whether a given compound will.
Lipinski’s rule of five
DATA MINING FOR SMALL MOLECULE ALLOSTERIC INHIBITORS
Virtual Screening.
“Structure Based Drug Design for Antidiabetics”
Presentation transcript:

Faculté de Chimie, ULP, Strasbourg, FRANCE Criblage virtuel Alexandre Varnek Faculté de Chimie, ULP, Strasbourg, FRANCE

Small Library of selected hits experimental computational Virtual Screening Filtering, QSAR, Docking Small Library of selected hits High Throughout Screening Hit Target Protein Large libraries of molecules

Virtual screening must be fast and reliable Chemical universe: 10200 molecules 1060 druglike molecules Virtual screening must be fast and reliable Molecules are considered as vectors in multidimentional chemical space defined by the descriptors 3

Candidat au développement Criblage à haut débit Cible HTS Criblage à haut débit High-throughput screening Hits Lead Génomique Analyse de données Optimisation Candidat au développement

Drug Discovery and ADME/Tox studies should be performed in parallel idea target combichem/HTS hit lead candidate drug ADME/Tox studies

Methodologies of a virtual screening

Platform for Ligand Based Virtual Screening ~106 – 109 molecules Filters Similarity search ~103 - – 104 molecules QSAR models Candidates for docking or experimental tests 7

Virtual Screening Molecules available for screening (1) Real molecules 1 - 2 millions in in-house archives of large pharma and agrochemical companies 3 - 4 millions of samples available commercially (2) Hypothetical molecules Virtual combinatorial libraries (up to 1060 molecules)

Methods of virtual High-Throughput Screening Filters Similarity search Classification and regression structure – property models Docking

Filters: Lipinski rules for drug-like molecules (« Rules of 5 ») H-bond donors < 5 (the sum of OH and NH groups); MWT < 500; LogP < 5 H-bond acceptors < 10 (the sum of N and O atoms without H attached).

Example of different filters: Rules for Absorbable compounds It is quite interesting to compare our permeability model to the Lipinski’s and Veber’s rules. All three models are described by similar parameters. The following table shows the maximum cut-off values for absorbable compounds in our data set. In bold we show cut-off values of Lipinski’s and Veber’s rules. By comparing these three columns we can see that in most cases the cut-off values of Lipinski’s and Veber’s rules have been exceeded by 100 percent. This observation has a dual explanation. First, all three models dealt with quite different biological phenomena. Lipinski analyzed compounds that reached the second phase of clinical trials. Veber analyzed oral bioavailability in rats (which is affected by metabolism to a much greater extend than HIA). Whereas we analyzed HIA. The second explanation is that all models have been derived using quite different analytical tools. We used C-SAR analysis that automatically considers a large variety of possible causes that determine poor permeability. Lipinski and Veber used conventional data mining techniques.

unsupervised and supervised approaches Similarity Search: unsupervised and supervised approaches 12

2d (unsupervised) Similarity Search Tanimoto coef Recherche par similarité; comparaison des clés structurales; 1 0 1 0 0 0 1 0 0 1 1 1 0 1 1 0 1 0 1 0 0 1 0 0 0 1 0 0 1 1 1 0 1 1 0 1 0 1 molecular fingerprints 13

Structural Spectrum of Thrombin Inhibitors structural similarity “fading away” … reference compounds 0.56 0.72 0.53 0.84 0.67 0.52 0.82 0.64 0.39

R. Guha et al. J.Chem.Inf.Mod., 2008, 48, 646 discontinuous SARs continuous SARs gradual changes in structure result in moderate changes in activity “rolling hills” (G. Maggiora) small changes in structure have dramatic effects on activity “cliffs” in activity landscapes Structure-Activity Landscape Index: SALIij = DAij / DSij DAij (DSij ) is the difference between activities (similarities) of molecules i and j R. Guha et al. J.Chem.Inf.Mod., 2008, 48, 646 Courtesy of Prof. J. Bajorath, University of Bonn

discontinuous SARs VEGFR-2 tyrosine kinase inhibitors MACCSTc: 1.00 Analog 6 nM 2390 nM small changes in structure have dramatic effects on activity “cliffs” in activity landscapes lead optimization, QSAR bad news for molecular similarity analysis... Courtesy of Prof. J. Bajorath, University of Bonn

Example of a “Classical” Discontinuous SAR Any similarity method must recognize these compounds as being “similar“ ... (MACCS Tanimoto similarity) Adenosine deaminase inhibitors

... when target structure is unknown Virtual Screening ... when target structure is unknown Virtual library Screening library Diverse Subset Parallel synthesis or synthesis of single compounds Design of focussed library Screening HTS Hits